2008

Trial Results: Immunology/Infectious Disease

Tuesday, October 7, 2008

Crucell and Sanofi Pasteur reported positive preliminary results from a phase II trial of CL-184, a vaccine for the treatment of rabies. This randomized, single-blind, controlled study enrolled 140 healthy subjects in the United States. The subjects received CL-184, a currently marketed human rabies immune globulin (HRIG) or placebo plus rabies vaccine.

[Read More]

Former etrials COO Named PDS President

Thursday, October 2, 2008

Former etrials chief operating officer Peter S. Benton is the newly named president of Phoenix Data Systems (PDS), the eClinical division of Newtown, Pa.-based CRO Bio-Imaging Technologies. Benton, whose position at etrials was eliminated in April, will succeed Dr. William Claypool, who is leaving PDS to start a pharmaceutical development consulting company. Bio-Imaging acquired PDS earlier this year.

[Read More]

Trial Results: Oncology

Wednesday, October 1, 2008

PharmaMar reported positive results from a phase III trial of Yondelis for the treatment of ovarian cancer. This randomized study enrolled 627 women with ovarian cancer who had relapsed after receiving standard first-line chemotherapy, across several international sites.

[Read More]

Guest Commentary: Clinical Trial Grant Writing

Thursday, September 25, 2008

Grant writing is a fundamental skill for every clinical researcher who seeks funding to conduct trials and advance medical care. Most grant reviewers have a limited amount of time to sift through a large number of proposals, so grants that are poorly written, disorganized or missing important information are likely to garner only a brief glance before being passed over. One way to guarantee your grant stands out compared to the rest is to make sure the statistical component of your study is well designed, complete, and clearly stated.

[Read More]